---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-23-000118"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:29:18.592386+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Pfizer expects to close Seagen acquisition on Dec 14; all regulatory approvals received

## Summary
- Expects to close Seagen acquisition on Dec 14, 2023 after receiving all required regulatory approvals.
- Irrevocably donates U.S. royalties from Bavencio (avelumab) sales to AACR to address FTC concerns.
- Creates Pfizer Oncology Division led by Chris Boshoff; splits non-oncology into U.S. and International divisions led by Aamir Malik and Alexandre de Germay.
- Angela Hwang leaves role as Chief Commercial Officer; will serve as advisor to CEO during transition.
- Plans analyst call on Dec 13 to discuss acquisition, new organization, and provide FY2024 financial guidance.

## SEC filing metadata
- accession: 0000078003-23-000118
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/pfe-20231207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-23-000118
- JSON: https://secwatch.observer/filing/0000078003-23-000118.json
- Plain text: https://secwatch.observer/filing/0000078003-23-000118.txt

## Key facts
- Executive change
  Alexandre de Germay was appointed as Chief International Commercial Officer at PFIZER INC.
  - Action: appointed
  - Role: Chief International Commercial Officer
  source text: the Pfizer International Commercial Division, which will be led by Alexandre de Germay, who will join Pfizer as Chief International Commercial Officer, Executive Vice President, and will report to Dr. Bourla.
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm
- Executive change
  Aamir Malik was appointed as Chief U.S. Commercial Officer at PFIZER INC.
  - Action: appointed
  - Role: Chief U.S. Commercial Officer
  source text: the Pfizer U.S. Commercial Division, which will be led by Aamir Malik, who will become Chief U.S. Commercial Officer, Executive Vice President, and continue reporting to Dr. Bourla
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm
- Executive change
  Angela Hwang resigned as Chief Commercial Officer at PFIZER INC.
  - Action: resigned
  - Role: Chief Commercial Officer
  source text: As a result of this reorganization, the role currently held by Angela Hwang, Chief Commercial Officer, Executive Vice President, is being eliminated and she will cease serving in her current role and as a member of the Company’s Executive Leadership Team effective as of December 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm
- Executive change
  Chris Boshoff was appointed as Chief Oncology Officer at PFIZER INC.
  - Action: appointed
  - Role: Chief Oncology Officer
  source text: Pfizer will create an end-to-end business organization called Pfizer Oncology Division, which will integrate certain Oncology Commercial and R&D operations from both Pfizer and Seagen and will be led by Dr. Chris Boshoff, who will become Chief Oncology Officer, Executive Vice President, and continue reporting to Dr. Albert Bourla, Chairman and Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.